Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

Samuel Cheshier(Primary Children's Hospital), Michael S. B. Edwards(Center for Cancer and Blood Disorders), Gary K. Steinberg(Palo Alto University), Gerald A. Grant(Duke University), Abdullah H. Feroze(Children's National), Michelle Monje(Howard Hughes Medical Institute), Gregor Hütter(University Hospital of Basel), Stephen B. Willingham(Silvus Technologies (United States)), Anne K. Volkmer(Institute for Stem Cell Biology and Regenerative Medicine), Vijay Ramaswamy(Hospital for Sick Children), Marc Remke(Saarland University), Patricia Lovelace(Institute for Stem Cell Biology and Regenerative Medicine), Eric H. Raabe(Johns Hopkins University), Siddhartha S. Mitra(Center for Infectious Disease Research), Chase Richard(Lucile Packard Children's Hospital), Hannes Vogel(Stanford University), Cyndhavi Narayanan(Stanford University), Theresa A. Storm(Institute for Stem Cell Biology and Regenerative Medicine), Ravindra Majeti(Stanford University), Irving L. Weissman(California Institute for Regenerative Medicine), Rogelio Esparza(Lucile Packard Children's Hospital), Michael Zhang(Stanford Medicine), Michael D. Taylor(Hospital for Sick Children), Jie Liu(Stanford University), Anitha Ponnuswami(Stanford University), Suzana Assad Kahn(Lucile Packard Children's Hospital), Simone Schubert(Stanford University), Griffith Harsh(Stanford University), Jens Volkmer(Institute for Stem Cell Biology and Regenerative Medicine), Pauline Chu(Stanford University), Paul G. Fisher(Northwestern University), Yoon-Jae Cho(Stanford Medicine)
Science Translational Medicine
March 15, 2017
Cited by 427


Related Papers